Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Plenaxis: One more try

Praecis Pharmaceuticals Inc.'s Plenaxis abarelix didn't achieve a slam dunk in a Phase II/III trial in endometriosis against Lupron leuprolide depot. And the company has not yet found a way around the increased loss in bone mineral density caused by the compound compared to Lupron. But results were sufficiently intriguing to keep PRCS in the game.

Last week, the company reported Phase II/III data showing that the compound failed to meet its short-term endpoint of superiority over Lupron from Tap Pharmaceuticals Inc. (Lake Forest, Ill.). The short-term

Read the full 861 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers